A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study

Circulation

Volumn 91, Issue 2, 1995, Pages 270-274

  Mattu, Raj K ^a,b   Needham, Edward W A ^a   Galton, David J ^a   Frangos, Evanthia ^a   Clark, Adrian J L ^a   Caulfield, Mark ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

angiotensin; coronary disease; enzymes; genes

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0028855768     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.91.2.270     Document Type: Article

References (46)

1. Yater WM, Traum AH, Brown WG, Fitzgerald RP, Geisler MA, Wilcox BB. Coronary artery disease in men eighteen to thirty-nine years of age. Am Heart J. 1948;36:334-372.
2. Slack J, Evans KA. The increased risk of death from ischaemic heart disease in first-degree relatives of 121 men and 96 women with ischaemic heart disease. J Med Genet. 1966;3:239-259.
3. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic-epidemiologic study of early onset ischaemic heart disease. Circulation. 1980;61:503-508.
4. Berg K. Twin studies of coronary heart disease and its risk factors. Acta Genet Med Gemellol (Roma). 1984;33:349-361.
5. Under Secretary of State for Wales. The Agenda for 1992-1994: Plans for Action Health for All in Wales. Cardiff HMSO, 1992.
6. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
7. Caldwell PRB, Seegal BC, Hsu KC, Soffer RL. Angiotensin-converting enzyme: vascular endothelial localisation. Science. 1976;191:1050-1051.
8. Ryan US, Ryan JW, Whitaker C, Chiu A. Localisation of angiotensin converting enzyme (kininase II), II: immunocytochemistry and immunofluorescence. Tissue Cell. 1976;8:125-145.
9. Erdös EG, Skidgel RA. The angiotensin I-converting enzyme. Lab Invest. 1987;56:346-348.
10. Skeggs LT Jr, Khan JR, Shumway NP. Preparation and function of the hypertension-converting enzyme. J Exp Med. 1956;103:295-299.
11. Yang HYT, Erdös EG, Levin Y. A dipeptide carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 1970;214:374-376.
12. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest. 1993;91:1453-1458.
13. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P. Two putative active centres in human angiotensin I converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA. 1988;85:9386-9390.
14. Mattei MG, Hubert C, Alhenc-Gelas F, Roeckel N, Corvol P, Soubrier F. Angiotensin-I converting enzyme gene is on chromosome 17. Cytogenet Cell Genet. 1989;51:1041.
15. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
16. Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin I-converting enzyme gene: two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol. Chem. 1991;266:15377-15383.
17. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidylcarboxypeptidase 1). Nucleic Acids Res. 1992;20:1433.
18. Cambien F, Poirier O, Lecerf L, Evans A, Cambou J-P, Arveiler D, Luc G, Bard J-M, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
19. The Caerphilly and Speedwell Collaborative Group. Caerphilly and Speedwell collaborative heart disease studies. J Epidemiol Community Health. 1984;38:259-262.
20. Rose GA, Blackburn H. Cardiovascular Survey Methods. 1st ed, no. 56. Geneva, Switzerland: World Health Organization; 1968.
21. Rose GA, Hamilton PJS, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischaemia, risk factors and death from coronary heart disease. Lancet. 1977;1:105-109.
22. Bainton D, Baker IA, Sweetnam PM, Yarnell JWG, Elwood PC. Prevalence of ischaemic heart disease: the Caerphilly and Speedwell surveys. Br Heart J. 1988;59:201-206.
23. Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) Study: prevalence of hyperlipidaemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116(6, pt 2):1713-1724.
24. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, Swales J. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993;306:983-987.
25. The Caerphilly Collaborative Heart Disease Studies. Project Description and Manual of Operations. London: MRC Epidemiology Unit; 1985:35-36.
26. Stocks J, Paul H, Galton DJ. Haplotypes identified by DNA polymorphisms in the AI-CIII-AIV gene region and hypertriglyceridaemia. Am J Hum Genet. 1987;41:106-118.
27. Kwock S, Higuchi R. Avoiding false positives with PCR. Nature. 1989;339:237-238.
28. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251-253.
29. Dux S, Aron N, Boner G, Carmel A, Taron A, Rosenfeld JB. Serum angiotensin converting enzyme activity in normal adults and patients with different types of hypertension. Isr J Med Sci. 1984;20:1138-1141.
30. Sassano P, Chatellier G, Billaud E, Alhenc-Gelas F, Corvol P, Menard J. Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalupril: a six-month double-blind trial. Am J Med. 1987;83:227-235.
31. Cambien F, Alhenc-Gelas F, Herbeth B, Andre JL, Rakotovao R, Gonzales MF, Allegrini J, Bloch C. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am J Hum Genet. 1988;43:774-780.
32. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM, Corvol P. Distribution of plasma angiotensin I-converting levels in healthy men: relationship to environmental and hormonal parameters. J Lab Clin Med. 1991;117:33-39.
33. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197-205.
34. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 1990;16:363-370.
35. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension. 1994;23:258-268.
36. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89:493-498.
37. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
38. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
39. Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction. Circulation. 1990;81:1161-1172.
40. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
41. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
42. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
43. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
44. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
45. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Benjamin-Perryman M. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993;342:1073-1075.
46. Marian AJ, Qun-tao Y, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342: 1085-1086.